Stocks · Health care · Pharmaceutical Preparations

LIGAND PHARMACEUTICALS INC

LGND Clue Score50
United States Fiscal year ends December CIK 0000886163 Results filed 29 Oct 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
120
$323.14
$38.78K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
200
$321.44
$64.29K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
320
$319.97
$102.39K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
440
$318.73
$140.24K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
280
$317.91
$89.01K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
80
$314.58
$25.17K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
403
$313.75
$126.44K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
634
$312.85
$198.35K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
520
$311.72
$162.09K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
490
$310.61
$152.20K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
522
$309.91
$161.77K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
708
$308.43
$218.37K
Andrew Reardon
2 Nov 2026
CLO & Secretary
Sold after exercise
283
$307.39
$86.99K

What was left out

Form 4 filings counted 3
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 13
Sales at will 6
Transactions with no price 0
Shares from compensation/vesting 5,000
History held since 29 Sep 2006